13th Nov 2026 11:45
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.
----------
MAIN MARKET SMALL-CAP WINNERS
----------
Gem Resources PLC, up 13% at 0.35p
----------
Defence Holdings PLC, up 11% at 0.50p
----------
Hemogenyx Pharmaceuticals PLC, up 7.6% at 671.50p, extends gains after announcing on Thursday that it has treated the first patient in the second cohort in HG-CT-1 ongoing phase I clinical trial
----------
SIG PLC, up 7.4% at 9.55p
----------
Residential Secure Income PLC, up 7.1% at 6.75p
----------
MAIN MARKET SMALL-CAP LOSERS
----------
Nostrum Oil & Gas PLC, down 18% at 0.35p
----------
Nanoco Group PLC, down 17% at 2.00p
----------
Neo Energy Metals PLC, down 11% at 0.39p
----------
IMC Exploration Group PLC, down 11% at 0.85p
----------
abrdn Property Income Trust Ltd, down 7.9% at 1.65p
----------
AIM WINNERS
----------
Mothercare PLC, up 25% at 0.20 pence
----------
Eden Biosolutions PLC, up 21% at 3.75p, US EPA registration granted for Mevalone Delta
----------
Sabien Technology Group PLC, up 17% at 3.50p
----------
Tooru PLC, up 10% at 0.16p, extends gains after securing a "significant listing" with "major UK retailer" on Thursday
----------
80 Mile PLC, up 8.7% at 1.03p, agrees all-share merger with Greenland Energy
----------
AIM LOSERS
----------
Caspian Sunrise PLC, down 31% at 0.92p, extends losses after shares resume trading on Thursday
----------
Secure Property Development & Investment PLC, down 17% at 0.40p
----------
Futura Medical PLC, down 13% at 0.24p
----------
ProService Building Services Marketplace PLC, down 9.8% at 3.70p
----------
Selkirk Group PLC, down 9.4% at 1.63p
----------
Small-cap and AIM movers in focus:
----------
Eden Biosolutions PLC, up 21% at 3.75 pence, 12-month range 2.00p-4.80p. The sustainable biopesticide developer announces that the US Environmental Protection Agency has granted unconditional federal registration for Mevalone Delta, its biofungicide designed to control fungal diseases across a range of high-value crops. The approval covers crops including grapes, almonds, strawberries and other berries, with a combined US farm-gate value of USD33 billion in 2024. Eden estimates the total addressable US market for Mevalone Delta at around USD144 million and expects to capture approximately 3% market share at peak sales. The product will now undergo state-level registration, expected to take between one and 12 months depending on the state, before commercial distribution through existing US partner Sipcam Agro USA. Mevalone Delta uses Eden's Sustaine microencapsulation technology and targets diseases including grey mould, powdery mildew and brown rot blossom blight. Chief Executive Sean Smith calls the approval a "significant milestone" for Eden in the US, saying it provides an opportunity to expand sales across North America as state registrations are secured.
----------
80 Mile PLC, up 8.7% at 1.03 pence, 12-month range 0.46p-1.54p. Shares rise after the Greenland-focused energy and critical minerals company announces on Thursday after the market close that it has agreed terms for a recommended all-share combination with Nasdaq-listed Greenland Energy Co, valuing 80 Mile about GBP74 million on a fully diluted basis. Under the proposed deal, 80 Mile shareholders will receive 0.0079485 of a new Greenland Energy share for each 80 Mile share held, valuing each 80 Mile share at 1.28p based on Greenland Energy's closing share price on Wednesday. This represents a 28% premium to 80 Mile's closing price of 1.00p on Wednesday and a 71% premium to its closing price before the offer period began in September. Upon completion, shareholders of each company will own about 50% of the combined business. The companies, which are already joint venture partners in Greenland's Jameson Land Basin project, say the merger will consolidate ownership of the project's licences and combine 80 Mile's assets with Greenland Energy's stronger financial position and access to US capital markets. Greenland Energy, which held USD37.4 million in cash at June 30, has agreed to provide 80 Mile with a GBP3 million convertible loan to support its operations ahead of completion. The independent directors of 80 Mile unanimously recommend the deal, which remains subject to shareholder, court and regulatory approvals.
----------
Touchstone Exploration Inc, down 7.9% at 9.00 pence, 12-month range 6.10p-12.00p. The oil and gas producer reports a 30% increase in petroleum and natural gas sales to USD16.5 million in the third quarter of 2026 from USD12.7 million a year earlier, supported by higher realised commodity prices despite lower production. Average realised prices rise to USD39.89 per barrel of oil equivalent from USD26.84 a year earlier. Average production falls to 4,485 barrels of oil equivalent per day from 5,142 a year earlier, but increases from the previous quarter. Touchstone says production averaged 5,020 barrels of oil equivalent per day in October, above the third-quarter average.
----------
Hemogenyx Pharmaceuticals PLC, up 7.6% at 671.50, 12-month range 356.00p-1,220.00p. Shares extend Thursday's gains after the clinical-stage biopharmaceutical company announced that it had treated the first patient in the second adult dose cohort of its phase I clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukaemia. The patient receives twice the dose administered to the three patients in the first cohort, following a recommendation from an independent safety monitoring board after no dose-limiting toxicities were observed.
----------
By Eva Castanedo, Alliance News senior economics reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Residential SecSIGHemogenyx PharmaceuticalsDefence HoldingsGem Resources PLCNostrum Oil&gasNanocoNeo Energy MetalsIMC Exploration Group PLCAbrdn PropertyMothercareSelkirk GroupFutura MedicalProservice BldgSecure PropCaspian Sunrise80 MileTooruSabien Tech.Eden Research